PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat
10 بازدیدها
• 07/08/23
0
0
جاسازی کنید
administrator
مشترکین
UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat
بیشتر نشان بده، اطلاعات بیشتر
نظرات فیس بوک
SORT BY-
نظرات برتر
-
آخرین نظرات